Form 4: Glaukos Director Gilbert Kliman Receives Equity Grant
Director Compensation Disclosure
Director Gilbert H. Kliman acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Corporation director compensation policy.
Summary
- Director Gilbert H. Kliman was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
- The director also received a grant of 2,987 stock options with an exercise price of $53.57.
- The total beneficial ownership for the director following these transactions is 37,406 shares.
- Both the RSUs and the stock options are scheduled to vest in full on the one-year anniversary of the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standardized compensation structure under the company's established Director Compensation Policy.
Negatives
- None identified; this is a routine disclosure of director compensation.
Risks
- Standard market risks associated with equity holdings and share price volatility.
Future Outlook
The equity grants are subject to a one-year vesting period, aligning the director's tenure with the company's future performance.
Industry Context
StockSavvy.ai notes that routine equity grants to board members are standard practice in the medical device industry to ensure governance alignment and retention of experienced directors.
Comparison to Industry Standards
- The compensation structure is consistent with standard corporate governance practices for mid-cap medical technology companies.
- Vesting schedules of one year for director equity are common among peers in the ophthalmic device sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of equity pursuant to the Issuer's Director Compensation Policy. | 05/28/2026 | Minimal; standard governance procedure. |
Stakeholder Impact
- Shareholders: Neutral impact as this is a standard compensation event.
Next Steps
- Vesting of the granted RSUs and stock options on May 28, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Transaction date for the grant of RSUs and stock options. |
| 05/28/2027 | Vesting date for the granted RSUs and stock options. |
| 05/28/2036 | Expiration date for the granted stock options. |
| 06/01/2026 | Date of filing. |
Keywords
Glaukos, GKOS, Director Compensation, Form 4, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.